These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 8525541)
1. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Vallera DA; Taylor PA; Vannice JL; Panoskaltsis-Mortari A; Blazar BR Transplantation; 1995 Dec; 60(11):1371-4. PubMed ID: 8525541 [TBL] [Abstract][Full Text] [Related]
2. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [TBL] [Abstract][Full Text] [Related]
3. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Teshima T; Ordemann R; Reddy P; Gagin S; Liu C; Cooke KR; Ferrara JL Nat Med; 2002 Jun; 8(6):575-81. PubMed ID: 12042807 [TBL] [Abstract][Full Text] [Related]
4. The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD. El-Hayek JM; Rogers TE; Brown GR J Leukoc Biol; 2005 Oct; 78(4):1001-7. PubMed ID: 16081594 [TBL] [Abstract][Full Text] [Related]
5. T-cell P/E-selectin ligand alpha(1,3)fucosylation is not required for graft-vs-host disease induction. Eom HS; Rubio MT; Means TK; Luster AD; Sykes M Exp Hematol; 2005 Dec; 33(12):1564-73. PubMed ID: 16338500 [TBL] [Abstract][Full Text] [Related]
6. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
7. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844 [TBL] [Abstract][Full Text] [Related]
8. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
9. Effect of donor and recipient gender disparities on fatal graft-vs.-host disease in a mouse model for major histocompatibility complex-matched unrelated-donor bone marrow transplantation. OKunewick JP; Kociban DL; Machen LL; Buffo MJ Exp Hematol; 1993 Nov; 21(12):1570-6. PubMed ID: 8405238 [TBL] [Abstract][Full Text] [Related]
10. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Anderson LD; Mori S; Mann S; Savary CA; Mullen CA Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776 [TBL] [Abstract][Full Text] [Related]
11. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746 [TBL] [Abstract][Full Text] [Related]
12. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Li JM; Gorechlad J; Larsen CP; Waller EK Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205 [TBL] [Abstract][Full Text] [Related]
13. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Jones SC; Friedman TM; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075 [TBL] [Abstract][Full Text] [Related]
14. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Drobyski WR; Majewski D; Hanson G Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102 [TBL] [Abstract][Full Text] [Related]